BiomX Inc. announced a private placement financing for expected gross proceeds of $3.0 million, with H.C. Wainwright & Co. as the exclusive placement agent. The Company will issue Series Y Convertible Preferred Stock and warrants with an aggregate value of $3.3 million, with each share accruing dividends at 15% per annum. The Private Placement is expected to close on December 30, 2025, and the net proceeds will be used for the Company’s bacteriophage programs, including BX011 for Staphylococcus aureus infections. The Securities sold in the Private Placement have not been registered and are subject to exemptions under the Securities Act.

Read more at GlobeNewswire: BiomX Announces $3.0 Million Private Placement